ClinicalTrials.gg
RecruitingNCT06302946Updated Mar 13, 2026

Effect of Neuromuscular Stimulation and Mindfulness Exercise in Patients With Stroke

An interventional study of neuromuscular stimulation and mindfulness and neuromuscular electrical stimulation in Stroke, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 50 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
50 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Stroke by Cairo University — 20 open to participants now, 22 under way, none of them phase 3. Stroke · Cairo University.

Planned enrollment
8th of 38
60 · median 40
Started
2026
with 11 others
No phase
38 of 41
19 open now
Primary completion
2026-12
later than 18 of 21 live
Registered
11th of 41
by date

Among the 41 studies in Stroke by Cairo University, this one is the 8th largest by planned enrollment of the 38 interventional ones that give a count, is one of 12 that started in 2026, is one of 38 with no phase, reaches primary completion later than 18 of the 21 other live ones, and was the 11th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

20 of the 41 studies in Stroke by Cairo University are open now, in 1 country. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 50 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Stroke by Cairo University, or all of them as a file.
02

Study summary

It is an interventional study in which 60 stroke patients were estimated to enroll according to random allocation and divided into two groups. The experimental group will receive neuromuscular stimulation and mindfulness , while the control group will receive neuromuscular stimulation only.

Read the detailed description

It is an interventional study in which 60 stroke patients will be estimated to enroll according to random allocation and divided into two groups. The experimental group will receive neuromuscular stimulation and mindfulness, while the control group will receive neuromuscular stimulation only. The experimental group participants will receive neuromuscular electrical stimulation that will last 12 consecutive weeks, three sessions per week protocol with Mindfulness.

03

Conditions studied

  • Stroke

Browse trials for

04

Who can participate

Ages eligible
50 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject selection will be according to the following criteria:
  • All Patients of this study will be diagnosed as stroke and the diagnosis will be confirmed by computed tomography or MRI (El-Tamawy et al., 2021).
  • Age of patients will be ranged from 50 to 65years (males and females).
  • All patients will be hemodynamically stable.
  • Patients with good cognition that enables them to understand the requirements of the study.

Exclusion criteria

Exclusion Criteria:

    • The potential participants will be excluded if they meet one of the following criteria:

      • Patients who cannot follow instructions as sensory aphasia, blindness, dementia, and deafness.
      • Patients with any orthopedic, neurological, or chest disorders that affect trunk muscles control or cause respiratory disorders as .
      • Patients with cognitive and psychiatric disorders.
      • Patients with unstable cardiovascular conditions.
      • Patients with to neuro electrical stimulation as:
      • Cardiac pace maker.
      • Acute abdominal surgery.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    experimental group

    will receive neuromuscular stimulation and mindfulness

    Other: neuromuscular stimulation and mindfulness

  • Active comparator
    control group

    The control group will receive neuromuscular stimulation only.

    Other: neuromuscular electrical stimulation

Interventions

  • Otherneuromuscular stimulation and mindfulness

    Receive neuromuscular stimulation and mindfulness breathing; the experimental group participants will receive neuromuscular electrical stimulation with Mindfulness.

  • Otherneuromuscular electrical stimulation

    participants in the control group perceived neuromuscular electrical stimulation

06

What researchers measure

Primary outcomes

  1. ventilatory function

    By a spirometer, forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), the ratio of forced vital capacity to forced expiratory volume (FEV1/FVC), and peak expiratory flow will be measured.

    Time frame: 12 weeks

Secondary outcomes

  1. level of stress

    perceived stress questionnaire Individual scores on the perceived stress questionnaire can range from 0 to 40 with higher scores indicating higher perceived tress

    Time frame: 12 weeks

  2. Functional independence measure

    The Functional independence measure consists of 18 measures organized into six dimensions and ranges from 18 to 126

    Time frame: 12 weeks

  3. level of physical function

    short physical performance battery group of measures that combines the results of the gait speed, chair stand and balance tests

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — sharing with other researches

Supporting information: Study protocol

Time frame: 12 months

Access criteria: after acceptance of publishing journal

Data sharing details ↗ · www.ekb.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Dec 2026, 8 months later.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 8 months is below that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2024
First posted
Mar 12, 2024
StartEst.
Mar 15, 2026
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 30, 2027
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06302946
Lead sponsor
Cairo University
Responsible party
marwa mahmoud elsayed mahmoud (assistant professor, Cairo University) — Principal investigator
First posted
Mar 12, 2024
Start date
Mar 15, 2026 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Mar 13, 2026

Study contacts

marwa elsayed, PhD
Contact
marwa.elsaid@cu.edu.eg
0201156033818
marwa elsayed
principal investigator · Cairo University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion